Scientists develop inhalable drug for tuberculosis treatment
Headline by Prism · from 1 report
Scientists at CSIR-CDRI are developing an inhalable drug to treat tuberculosis by delivering medicine directly to the lungs.
1 of 32 monitored outlets · 1 report · Hindi · checked
Amar UjalaThe brief
Written by software from the 1 report below.
- Tuberculosis remains a significant public health challenge in India with high infection and mortality rates.
- Researchers at the CSIR-Central Drug Research Institute have developed a new medication combining rifabutin and isoniazid.
- This treatment is designed to be inhaled directly into the lungs to target the infection at its source.
- Animal testing has been completed and human trials are currently being prepared under regulatory guidance.
What to watch next
- Commencement of phase-1 human clinical trials on healthy individuals.
- Submission of additional safety data to the Central Drugs Standard Control Organization.
- Progress of ALS treatment trials discussed by the expert committee.
The points restate the reports; where one says why it matters, that is Prism's reading, not a reported fact.
Coverage
1 outlet
Indian-language1
All filed from India
NamedIndia · Central Drug Research Institute · Central Drugs Standard Control Organization · World Health Organization
The 1 report is listed beside the record.
Corrections and versions
A correction says what was wrong and why. Every earlier headline and brief of this record is kept.
Something wrong?
Say what, and it arrives with this record's address filled in. A correction is welcome.
Ask this story
Answers cite the 1 report above, or say they can't.